Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intravenous thrombolysis for acute stroke.

Joseph P Broderick1

  • 1Department of Neurology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0525, USA.

Cleveland Clinic Journal of Medicine
|February 18, 2004
PubMed
Summary

Intravenous thrombolysis with tissue plasminogen activator (t-PA) is effective within 3 hours of stroke onset. Careful patient selection and monitoring ensure safety, but optimal dosing and use beyond 3 hours require further study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intracranial Aneurysm-Associated COL22A1 Variants Impair Cerebrovascular Structure and Barrier Integrity in Zebrafish.

International journal of molecular sciences·2026
Same author

Advances in Acute Ischemic Stroke 2025: Medical Treatments.

Stroke·2026
Same author

Vascular Neurology Fellowship: Where Do We Go From Here?

Stroke·2026
Same author

Transcranial Direct Current Stimulation for Stroke Motor Recovery What the TRANSPORT2 Trial Taught Us.

Stroke·2026
Same author

Apixaban Versus Aspirin and Risk of Hemorrhage in the ARCADIA Trial.

Annals of neurology·2026
Same author

Ten years of Central IRB review for an NIH-funded large clinical trial network by an academic IRB: The NIH StrokeNet experience.

Journal of clinical and translational science·2026

Area of Science:

  • Neurology
  • Emergency Medicine
  • Pharmacology

Background:

  • Intravenous tissue plasminogen activator (t-PA) is a critical treatment for acute ischemic stroke.
  • Timely administration of t-PA is crucial for maximizing its effectiveness.
  • Established protocols ensure the safe use of t-PA within a defined time window.

Purpose of the Study:

  • To evaluate the effectiveness and safety of intravenous t-PA in acute ischemic stroke.
  • To explore potential optimizations in t-PA dosing and administration timing.
  • To investigate advanced imaging techniques for patient selection beyond the standard time window.

Main Methods:

  • Review of existing literature on intravenous t-PA in stroke treatment.
  • Analysis of safety parameters including blood pressure management, anticoagulation avoidance, and patient monitoring.
  • Exploration of diffusion/perfusion MRI for extended treatment eligibility.

Main Results:

  • Intravenous t-PA demonstrates significant effectiveness when administered within 3 hours of stroke onset, with earlier administration yielding better outcomes.
  • Safe use is achievable with strict adherence to protocols, including blood pressure control and avoidance of concurrent anticoagulants.
  • The efficacy and safety of lower t-PA doses and administration beyond 3 hours remain subjects for further investigation.

Conclusions:

  • Intravenous t-PA is a highly effective and reasonably safe treatment for acute ischemic stroke within the 3-hour window when administered promptly and under strict protocols.
  • Further research is needed to determine optimal dosing strategies and the potential benefits of t-PA in patients presenting beyond the 3-hour timeframe.
  • Advanced imaging may help identify suitable candidates for thrombolysis outside the conventional time window, though the associated delays must be considered.

Related Experiment Videos